Sobi has announced positive topline results from a pivotal phase 3 study evaluating pozdeutinurad (AR882), an investigational next-generation once-daily oral selective URAT1 inhibitor, in adults with gout including those with uncontrolled gout (also referred to as progressive gout) and inadequately controlled by existing therapies.
Both doses of pozdeutinurad met the primary efficacy endpoint, defined as the proportion of patients achieving a serum uric acid (sUA) level <6 mg/dL at month six (75 mg: 69.2% vs 8.1%; p<0.0001; 50 mg: 56.6% vs 8.1%; p<0.0001). The safety profile was consistent with previous studies. Detailed results are expected to be presented at a forthcoming scientific congress in quarter four.
Pozdeutinurad was added to Sobi’s global development portfolio in February 2026 following its acquisition of Arthrosi, a biotechnology company focused on developing treatments for gout, and further enhances Sobi’s presence in this area. Pozdeutinurad is being investigated in two global phase 3 studies, which are 12-month, randomised, double-blind, placebo-controlled trials designed to evaluate pozdeutinurad in patients with gout, including those with tophaceous gout.
They enrolled more than 800 patients each.
The first study is fully enrolled and data are expected in the second half of 2026.
